Search Results - "STANER, C"

The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells by Joly, S, Porcherot, M, Radreau, P, Vonderscher, J, André, P, Meldrum, E, Arold, G, Van de Wetering de Rooij, J, Staner, C, Laveille, C, Scalfaro, P

Get full text

Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers by Otmani, Sarah, Demazieres, Agnes, Staner, Corinne, Jacob, N, Nir, Tali, Zisapel, Nava, Staner, Luc

“…Background Melatonin is an important regulator of the sleep–wake cycle. A prolonged‐release formulation of melatonin (PR‐M) that essentially mimics the profile…”
Get full text

Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia by LUNDAHL, J, STANER, L, STANER, C, LOFT, H, DEACON, S

“…Gaboxadol is a selective extrasynaptic GABA(A) agonist, previously in development for the treatment of insomniac patients. To evaluate the acute efficacy and…”
Get full text

S.09.04 New pharmacological treatments for negative symptoms: pitfalls and future perspectives of clinical trials by Davidson, M., Saoud, J., Staner, C., Luthringer, E., Luthringer, R.

Get full text

Reversal of “Schizofrenia-like” and “Dementia-like” MMN deficits induced by blockade of excitatory pathways in humans effects of indirect NMDA-modulators by C., Staner

“…Abstract only…”
Get full text

P.3.d.001 - Efficacy and safety of MIN-101: a new drug in development for the treatment of negative symptoms in schizophrenia – a 12 weeks RCT by Davidson, M., Jay, S., Staner, C., Luthringer, E., Noel, N., Reilly, J., Weiser, M., Rabinowitz, J., Luthringer, R.

Get full text

Efficacy and safety of MIN-101: a new drug in development for the treatment of negative symptoms in schizophrenia – a 12 weeks RCT by Davidson, M., Jay, S., Staner, C., Luthringer, E., Noel, N., Reilly, J., Weiser, M., Rabinowitz, J., Luthringer, R.

Get full text

SAT-158 - The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells by Joly, S., Porcherot, M., Radreau, P., Vonderscher, J., André, P., Meldrum, E., Arold, G., Van de Wetering de Rooij, J., Staner, C., Laveille, C., Scalfaro, P.

Get full text

Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia by Staner, Luc, Cornette, Françoise, Maurice, Damien, Viardot, Geoffrey, Bon, Olivier Le, Haba, José, Staner, Corinne, Luthringer, Rémy, Muzet, Alain, Macher, Jean‐Paul

“…Summary In the present study we investigate whether alterations of sleep propensity or of wake propensity are implicated in sleep initiation disturbances…”
Get full text